The most influential Megatrends set to shape the world through 2030, identified by Euromonitor International, help businesses better anticipate market developments and lead change for their industries.
Learn moreEuromonitor addresses your unique questions and challenges across all B2B and B2C industries and geographies through custom, tailor-made research projects, designed to your specific goals.
Learn moreDec 2017
US$570Added to Cart
If you purchase a report that is updated in the next 60 days, we will send you the new edition and data extract FREE!
If you purchase a report that is updated in the next 60 days, we will send you the new edition and data extract FREE!
Vitamin and dietary supplements (VDS) positioned as “immune boosters” or for “immune support” are very popular in the US market and growing more so, as consumers look to natural, preventive products to stave off seasonal colds and the flu. Loose restrictions around health claims make it easy for new products to enter the market, and consumers are increasingly drawn toward VDS products directed at a broader health positioning (such as “immunity” and “energy”) over products for a specific symptom.
Files are delivered directly into your account within a few minutes of purchase.
Gain competitive intelligence about market leaders. Track key industry trends, opportunities and threats. Inform your marketing, brand, strategy and market development, sales and supply functions.
More than two thirds of US consumers report routine use of VDS products, and the vast majority also report trusting VDS products to be safe and to do what they claim they will do. Of these consumers, almost 30% report taking VDS products positioned for “immune health” or “immune support.”
It is very easy for VDS products to claim a role in immune support, too, since the US Food & Drug Administration (FDA) has very loose restrictions regarding what a VDS product can legally claim that it does. Because it is so easy for new products to enter this space, more and more products are being released in the US market, driving up competition.
Within consumer health, and VDS in particular, consumers are increasingly shifting their purchasing choices away from products directed at a specific symptom (like “pain”) and more towards products that address wider health systems (such as “immune support”, “energy boosting”, or “heart health”.) Broader health benefits are preferred to individual benefits that may not have as prolonged or extensive results.
Among products positioned for immune defence, the US market is dominated by Emergen-C (Pfizer) and Airborne (RB). Sales of both products have grown rapidly in recent years, with increases in absolute retail value sales of USD102 million and USD44 million, respectively, between 2012 and 2017.
Gain competitive intelligence about market leaders. Track key industry trends, opportunities and threats. Inform your marketing, brand, strategy and market development, sales and supply functions.